GlassScriptPhysician profile
Michelle Delich
NPI 1114640612
$2,632.39
in general payments reported to CMS, 2019-2025
32 companies · $1,198 in 2025
The $1,198 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $150 · 2023: $755 · 2024: $530 · 2025: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,363 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,362.56 |
| Education | $119.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $527.01 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $233.63 | 2025 | Opdivo |
| Bayer Healthcare Pharmaceuticals INC. | $219.62 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $190.68 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $163.63 | 2023-2025 | Breztri, Enhertu |
| Abbvie INC. | $139.95 | 2023 | |
| Lilly USA, LLC | $137.77 | 2023-2025 | Mounjaro, Zepbound |
| Myriad Women'S Health, INC. | $115.05 | 2023 | Myrisk |
| Lexicon Pharmaceuticals, INC. | $97.45 | 2024 | Inpefa |
| Pfizer INC. | $88.44 | 2022-2023 | |
| Axsome Therapeutics, INC. | $71.08 | 2025 | Sunosi |
| Xeris Pharmaceuticals, INC. | $59.35 | 2023 | Keveyis, Gvoke Hypopen |
| Genentech USA, INC. | $50.10 | 2025 | Tecentriq, Columvi |
| Sobi, INC | $48.56 | 2023-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $47.65 | 2024-2025 | Lumryz |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $41.30 | 2025 | |
| Lundbeck LLC | $40.14 | 2023 | Rexulti |
| Philips North America LLC | $39.32 | 2023 | |
| Zoll Respicardia, INC. | $34.51 | 2024 | Remede System |
| Syndax Pharmaceuticals, INC. | $32.44 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.54 | 2025 | Fruzaqla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.16 | 2022 | |
| Fisher & Paykel Healthcare INC | $24.07 | 2025 | Fisher & Paykel Healthcare |
| Servier Pharmaceuticals LLC | $24.00 | 2025 | |
| Beone Medicines USA, INC. | $23.26 | 2025 | Brukinsa |
| Corcept Therapeutics | $22.28 | 2022 | |
| Janssen Biotech, INC. | $21.04 | 2025 | Rybrevant |
| Amgen INC. | $20.99 | 2023 | Repatha, Otezla |
| Mannkind Corporation | $18.96 | 2022 | |
| Hologic Sales and Service, LLC | $16.91 | 2024 | Aptima |
| Kowa Pharmaceuticals America, INC. | $15.77 | 2023 | Livalo, Seglentis |
| Lucid Diagnostics INC. | $13.73 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Delich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.